Production Processes of Licensed Recombinant Factor VIII Preparations

ABSTRACT

The state-of-the-art treatment for hemophilia A is replacement therapy with recombinant factor VIII (rFVIII) made possible by genetic engineering advances. Currently, there are four different products licensed and available for hemophilia A patients. All are produced by recombinant mammalian cells in large-scale fermenter cultures, purified to high purity, formulated in stable formulations and freeze dried. The first-generation products Recombinate® and Kogenate® (also sold as Helixate® by Aventis) are characterized as full-length human factor VIII molecules and formulated using human serum albumin as a stabilizer. The second-generation product ReFacto® contains an improved albumin-free sucrose formulation and incorporates advanced antiviral safety procedures in the manufacturing process. It is a truncated B region-deleted form of factor VIII (FVIII) that makes use of a nonhuman peptide linker 14 amino acids in length to connect the 80 and 90 kD subunits. The most recently licensed rFVIII product is the second-generation Kogenate product called KOGENATE®Bayer/Kogenate® FS, which combines the advantages of the human full-length FVIII molecule with an albumin-free, sucrose-based synthetic formulation as well as an improved viral safety profile. In this article, the manufacturing processes for each of the four different products are discussed in detail, focusing on expression systems and cell lines, culture medium, technical culture systems, purification process (including viral removal potential), and final formulation.

KEYWORD

Mammalian cell culture - virus safety - Helixate® - Kogenate® - KOGENATE® - Bayer/Kogenate® - FS - Recombinate® - ReFacto®

REFERENCES

• 1 Kogenate® Product Monograph, Bayer, 1993.
• 2 Recombinate® Product Monograph, Baxter Hyland, 1992.
• 3 ReFacto® Product Monograph, Wyeth-Ayerst (Genetic Institute), 1999.
• 4 KOGENATE® Bayer Product Monograph, Bayer, 2000.
• 5 Harmening, D M. Clinical Hematology and Fundamentals, 2nd ed. Philadelphia: FA Davis; 1992;0:415-438 . 
• 6 Vehar G A, Keyt B, Eaton D. Structure of human factor VIII.  Nature . 1984;  312 337-342
• 7 Toole J J, Knopf J L, Wozney J M. Molecular cloning of a cDNA encoding human anithemophilic factor.  Nature . 1984;  312 342-347
• 8 White G C, Shoemaker C B. Factor VIII gene and hemophilia A.  Blood . 1989;  73 1-12
• 9 Wood W I, Capon D J, Simonsen C C. Expression of active human factor VIII from recombinant DNA clones.  Nature . 1984;  312 330-337
• 10 Boedeker B GD. The manufacturing of recombinant factor VIII, Kogenate®.  Trans Med Rev . 1992;  6 256-260
• 11 Gomperts E, Lundblad R, Adamson R. The manufacturing of recombinant factor VIII, Recombinate®.  Trans Med Rev . 1992;  6 247-251
• 12 Boedeker B GD, Newcomb R, Yuan P, et. Production of recombinant factor VIII from perfusion cultures: I Large scale fermentation. In: Spier RE, Griffiths JB, Berthold W, eds. Animal Cell Technology: Products of Today, Prospects of Tomorrow Oxford, England: Butterworth-Heinemann 1994: 580-583
• 13 Boedeker B GD, Potere E, Dove G. Production of recombinant factor VIII from perfusion cultures: II Large scale purification. In: Spier RE, Griffiths JB, Berthold W, eds. Animal Cell Technology: Products of Today, Prospects of Tomorrow Oxford, England: Butterworth-Heinemann 1994: 584-587
• 14 Horowitz B, Horowitz B, Wiebe M E. Inactivation of viruses in labile blood derivatives: disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combination.Transfusion .  1985;  25 516-522
• 15 Arnold D. Virus safety considerations for recombinant factor VIII (rFVIII, Kogenate®).  Haemophilia . 1995;  1(Suppl 2) 22-23
• 16 Kaufman R J. Insight into the structure, function and biosynthesis of factor VIII through recombinant DNA technology.  Ann Hematol . 1991;  63 155-165
• 17 Adamson R. Design and operation of a recombinant mammalian cell manufacturing process.  Ann Hematol . 1994;  68 S9-S14
• 18 Kaufmann R J, Wasley L C, Davis M V. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in CHO cells.  Mol Cell Biol . 1989;  9 1233-1242
• 19 Koplove H M. Cell culture and purification process-purity and safety testing.  Ann Hematol . 1994;  68 S15-S20
• 20 Lawrence J. Recombinate®: viral safety and final product manufacturing testing and specifications.  Ann Hematol . 1994;  68 S21-S24
• 21 Lind P, Larsson K, Spira J. Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization.  Eur J Biochem . 1995;  232 19-27
• 22 Berntrop E. Second generation, B-domain deleted recombinant factor VIII.  Thromb Haemost . 1997;  78 256-260
• 23 Österberg T, Fatouros A, Mikaelsson M. Development of a freeze-dried albumin-free formulation for recombinant factor VIII SQ.  Pharm Res . 1997;  14 892-898
• 24 Pollmann H, Aledort L. Albumin-free formulated recombinant factor VIII preparations-how big a step forward?.  Thromb Haemost . 1999;  82 1370-1371
• 25 Snyder M, Carrillo R, Frankenberg R. New manufacturing process for recombinant antihemophilic factor (rFVIII).  Thromb Haemost . 1997;  78(Suppl) 509 Abstract 
• 26 Nayar R, Wang D Q, Temple S. Recombinate Kogenate® formulation development.  Thromb Haemost . 1997;  78(Suppl) 509 Abstract 
• 27 Abshire T C, Brackmann H H, Scharrer I. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy.  Thromb Haemost . 2000;  83 811-816